SU5416, a receptor tyrosine kinase inhibitor, is active in preclinical models of acute myeloid leukemia.

被引：0
|
作者：
Bertolini, F
Dell'Agnola, C
Gobbi, A
Monestiroli, S
Pruneri, G
McMahon, G
Martinelli, G
机构：
[1] European Inst Oncl, Milan, Italy
[2] Sugen Inc, San Francisco, CA USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
505
引用
收藏
页码：117A / 117A
页数：1
相关论文
共 50 条
  • [1] SU5416,a novel receptor tyrosine kinase inhibitor, in the treatment of patients with refractory, c-kit positive, acute myeloid leukemia.
    Fiedler, W
    Mesters, R
    Staib, P
    Kuse, R
    Duehrsen, U
    Flasshove, M
    Truemper, L
    Cavalli, F
    Ottmann, O
    Kelsey, S
    Scigalla, P
    Loges, S
    Tinnefeld, H
    Hossfeld, DK
    Berdel, WE
    BLOOD, 2001, 98 (11) : 124A - 124A
  • [2] Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
    Mesters, RM
    Padró, T
    Bieker, R
    Steins, M
    Kreuter, M
    Göner, M
    Kelsey, S
    Scigalla, P
    Fiedler, W
    Büchner, T
    Berdel, WE
    BLOOD, 2001, 98 (01) : 241 - 243
  • [3] SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
    Giles, FJ
    Stopeck, AT
    Silverman, LR
    Lancet, JE
    Cooper, MA
    Hannah, AK
    Cherrington, JM
    O'Farrell, AM
    Yuen, HA
    Louie, SG
    Hong, W
    Cortes, JE
    Verstovsek, S
    Albitar, M
    O'Brien, SM
    Kantarjian, HM
    Karp, JE
    BLOOD, 2003, 102 (03) : 795 - 801
  • [4] Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia
    O'Farrell, AM
    Yuen, HA
    Smolich, B
    Hannah, AL
    Louie, SG
    Hong, WR
    Stopeck, AT
    Silverman, LR
    Lancet, JE
    Karp, JE
    Albitar, M
    Cherrington, JM
    Giles, FJ
    LEUKEMIA RESEARCH, 2004, 28 (07) : 679 - 689
  • [5] Inhibition of RET tyrosine kinase by SU5416
    Mologni, Luca
    Sala, Elisa
    Cazzaniga, Sara
    Rostagno, Roberta
    Kuoni, Thomas
    Puttini, Miriam
    Bain, Jenny
    Cleris, Loredana
    Redaelli, Sara
    Riva, Barbara
    Formelli, Franca
    Scapozza, Leonardo
    Gambacorti-Passerini, Carlo
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2006, 37 (02) : 199 - 212
  • [6] A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
    Fiedler, W
    Mesters, R
    Tinnefeld, H
    Loges, S
    Staib, P
    Dührsen, U
    Flasshove, M
    Ottmann, OG
    Jung, WF
    Cavalli, F
    Kuse, R
    Thomalla, J
    Serve, H
    O'Farrell, AM
    Jacobs, M
    Brega, NM
    Scigalla, P
    Hossfeld, DK
    Berdel, WE
    BLOOD, 2003, 102 (08) : 2763 - 2767
  • [7] The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
    Smolich, BD
    Yuen, HA
    West, KA
    Giles, FJ
    Albitar, M
    Cherrington, JM
    BLOOD, 2001, 97 (05) : 1413 - 1421
  • [8] Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma
    Peterson, AC
    Swiger, S
    Stadler, WM
    Medved, M
    Karczmar, G
    Gajewski, TF
    CLINICAL CANCER RESEARCH, 2004, 10 (12) : 4048 - 4054
  • [9] Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
    Mendel, DB
    Laird, AD
    Smolich, BD
    Blake, RA
    Liang, CX
    Hannah, AL
    Shaheen, RM
    Ellis, LM
    Weitman, S
    Shawver, LK
    Cherrington, JM
    ANTI-CANCER DRUG DESIGN, 2000, 15 (01): : 29 - 41
  • [10] Phase II clinical-laboratory of the anti-angiogenesis receptor tyrosine kinase (RTK) inhibitor, SU5416 in refractory acute myelogenous leukemia (AML) and myelodysplasia (MDS).
    Karp, JE
    Stopeck, A
    Albitar, M
    Silverman, L
    Lancet, JE
    Jacobs, M
    Ofarrell, M
    Hannah, A
    Cherrington, J
    Giles, FJ
    BLOOD, 2001, 98 (11) : 118A - 118A
12345